Asset Details
Do you wish to reserve the book?
Targeting axonal guidance dependencies in glioblastoma with ROBO1 CAR T cells
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Targeting axonal guidance dependencies in glioblastoma with ROBO1 CAR T cells
Do you wish to request the book?
Targeting axonal guidance dependencies in glioblastoma with ROBO1 CAR T cells
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Targeting axonal guidance dependencies in glioblastoma with ROBO1 CAR T cells
2024
Overview
Resistance to genotoxic therapies and tumor recurrence are hallmarks of glioblastoma (GBM), an aggressive brain tumor. In this study, we investigated functional drivers of post-treatment recurrent GBM through integrative genomic analyses, genome-wide genetic perturbation screens in patient-derived GBM models and independent lines of validation. Specific genetic dependencies were found consistent across recurrent tumor models, accompanied by increased mutational burden and differential transcript and protein expression compared to its primary GBM predecessor. Our observations suggest a multi-layered genetic response to drive tumor recurrence and implicate PTP4A2 (protein tyrosine phosphatase 4A2) as a modulator of self-renewal, proliferation and tumorigenicity in recurrent GBM. Genetic perturbation or small-molecule inhibition of PTP4A2 acts through a dephosphorylation axis with roundabout guidance receptor 1 (ROBO1) and its downstream molecular players, exploiting a functional dependency on ROBO signaling. Because a pan-PTP4A inhibitor was limited by poor penetrance across the blood–brain barrier in vivo, we engineered a second-generation chimeric antigen receptor (CAR) T cell therapy against ROBO1, a cell surface receptor enriched across recurrent GBM specimens. A single dose of ROBO1-targeted CAR T cells doubled median survival in cell-line-derived xenograft (CDX) models of recurrent GBM. Moreover, in CDX models of adult lung-to-brain metastases and pediatric relapsed medulloblastoma, ROBO1 CAR T cells eradicated tumors in 50–100% of mice. Our study identifies a promising multi-targetable PTP4A–ROBO1 signaling axis that drives tumorigenicity in recurrent GBM, with potential in other malignant brain tumors.
Publisher
Nature Research,Nature Publishing Group US,Nature Publishing Group
Subject
/ Animals
/ Biomedical and Life Sciences
/ Brain Neoplasms - immunology
/ CRISPR
/ Female
/ Glioma
/ Humans
/ Immunotherapy, Adoptive - methods
/ Mice
/ Neoplasm Recurrence, Local - genetics
/ Neoplasm Recurrence, Local - pathology
/ Nerve Tissue Proteins - genetics
/ Nerve Tissue Proteins - metabolism
/ Patients
/ Protein Tyrosine Phosphatases - genetics
/ Protein Tyrosine Phosphatases - metabolism
/ Protein-tyrosine-phosphatase
/ Proteins
/ Receptors, Chimeric Antigen - genetics
/ Receptors, Chimeric Antigen - immunology
/ Receptors, Chimeric Antigen - metabolism
/ Receptors, Immunologic - genetics
/ Receptors, Immunologic - metabolism
/ Roundabout Proteins - antagonists & inhibitors
/ Tumors
/ Tyrosine
